Literature DB >> 1735678

Tumor blood flow changes induced by chemical modifiers of radiation response.

D J Chaplin1, M R Horsman.   

Abstract

This study was designed to investigate blood flow changes induced by chemical agents that are commonly used in combination with radiation therapy. The hypoxic cell cytotoxin RSU 1069 at a dose of 100 mg/kg was shown to reduce blood flow by 80% in both SCCVII and C3H mammary tumors. Blood flow reductions of 30-40% were also observed in both tumors following administration of the radiation sensitiser pimonidazole (Ro-03-8799) at a dose of 500 mg/kg. Moreover studies in the C3H mammary tumor indicated that this effect was tumor size-dependent, being more profound and of longer duration in 500 mg than in 100 mg tumors. Blood flow decreases were also observed in the SCCVII tumor after administration of adriamycin at a dose of 15 mg/kg. Blood flow decreased by over 80% immediately after drug administration but recovered to remain 20% below control values 1 hr after drug administration. In contrast to the other agents studied, cis platinum at a dose of 2 mg/kg produced a small 20-30% increase in blood flow which persisted over the 1 hr observation period. The potential implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735678     DOI: 10.1016/0360-3016(92)90853-a

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

2.  Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

Authors:  D J Chaplin; G R Pettit; C S Parkins; S A Hill
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.

Authors:  E O Aboagye; R J Maxwell; M R Horsman; A D Lewis; P Workman; M Tracy; J R Griffiths
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.